Literature DB >> 23643910

Loss of ELF3 immunoexpression is useful for detecting oral squamous cell carcinoma but not for distinguishing between grades of epithelial dysplasia.

Ahmad A AbdulMajeed1, Andrew J Dalley, Camile S Farah.   

Abstract

Early diagnosis and targeted therapy are crucial to mitigating the morbidity and mortality of oral squamous cell carcinoma. Among the potentially malignant oral disorders, epithelial dysplasia has known association with malignant transformation, but defensible gradation of dysplasia severity presents unmet challenges. Published microarray data has denoted dysregulation of CLSP, ELF3, IFI44, USP18, and CXCL13 genes in potentially malignant oral disorders. The present study investigated the diagnostic potential of these gene products to grade oral epithelial dysplasia severity. Archived biopsies from independent patient cohorts comprised "training" (n=107) and "test" (n=278) sample sets. Immunoreactivity for candidate markers was determined in the "training" set of normal oral mucosa (NOM), mild dysplasia (MD), moderate to severe dysplasia, and oral squamous cell carcinoma (OSCC). The diagnostic potential of ELF3 immunoscoring to improve detection and severity gradation of epithelial dysplasia was assessed with the "test" set. A reciprocal relationship between disease severity and immunoreactivity score for CLSP and ELF3 was observed (MD/NOM to OSCC: P<.08, Mann-Whitney U test), whereas elevated IFI44 immunostaining was present for OSCC compared to MD/NOM (P<.08, Mann-Whitney U test). Loss of ELF3 immunostaining effectively distinguished OSCC from non-malignant tissues (sensitivity=0.81; specificity=0.56; area under the curve [AUC]=0.68) but did not distinguish dysplasia from NOM (sensitivity=0.55; specificity=0.40; AUC=0.47) or moderate to severe dysplasia from MD (sensitivity=0.63; specificity=0.51; AUC=0.57). The results confirm via immunohistochemistry the relevance of published CLSP, ELF3, and IFI44 (but not USP18 or CXCL13) gene expression data to potentially malignant oral lesion severity. Loss of ELF3 immunostaining discriminated OSCC from dysplasia but was unreliable for grading dysplasia severity.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CLSP; ELF3; Immunohistochemistry; Oral epithelial dysplasia; Oral squamous cell carcinoma; Organotypic culture

Mesh:

Substances:

Year:  2013        PMID: 23643910     DOI: 10.1016/j.anndiagpath.2013.03.003

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  5 in total

Review 1.  Can immunohistochemistry serve as an alternative to subjective histopathological diagnosis of oral epithelial dysplasia?

Authors:  Ahmad A Abdulmajeed; Camile S Farah
Journal:  Biomark Cancer       Date:  2013-10-10

2.  ETS transcription factor ELF3 (ESE-1) is a cell cycle regulator in benign and malignant prostate.

Authors:  Leanne K Archer; Fiona M Frame; Hannah F Walker; Alastair P Droop; Georgina L K McDonald; Samuel Kucko; Daniel M Berney; Vincent M Mann; Matthew S Simms; Norman J Maitland
Journal:  FEBS Open Bio       Date:  2022-05-06       Impact factor: 2.792

Review 3.  Gene expression profiling for the purposes of biomarker discovery in oral potentially malignant lesions: a systematic review.

Authors:  Ahmad A Abdulmajeed; Camile S Farah
Journal:  Clin Med Insights Oncol       Date:  2013-10-31

4.  Mechanistic insights into transcription factor cooperativity and its impact on protein-phenotype interactions.

Authors:  Ignacio L Ibarra; Nele M Hollmann; Bernd Klaus; Sandra Augsten; Britta Velten; Janosch Hennig; Judith B Zaugg
Journal:  Nat Commun       Date:  2020-01-08       Impact factor: 14.919

5.  FOXP4 inhibits squamous differentiation of atypical cells in cervical intraepithelial neoplasia via an ELF3-dependent pathway.

Authors:  Takeo Matsumoto; Takashi Iizuka; Mitsuhiro Nakamura; Takuma Suzuki; Megumi Yamamoto; Masanori Ono; Kyosuke Kagami; Haruki Kasama; Kousho Wakae; Masamichi Muramatsu; Shin-Ichi Horike; Satoru Kyo; Yasuhiko Yamamoto; Yasunari Mizumoto; Takiko Daikoku; Hiroshi Fujiwara
Journal:  Cancer Sci       Date:  2022-08-01       Impact factor: 6.518

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.